个人科研网厅 | | 帮助
首都医科大学宣武医院知识库
高级检索
当前位置： 首页 > 详情页

Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis A single institution retrospective analysis

| 认领 | 导出 | |

文献详情

资源类型：

收录情况： ◇ SCIE

作者：
Hualin Chen,[a,b] * ; Aibing Wu,[b] ; Hua Tao,[c] ; Donghong Yang,[b] ; Yiping Luo,[b] ; Shujun Li,[b] ; Zhixiong Yang,[b] ; Ming Chen,[a,d,*1] ;
机构： [a]Department of Oncology, the Second Affiliated Hospital of Soochow University, Jiangsu Province, Suzhou, [b]Cancer Center, Affiliated Hospital of Guangdong Medical University, Guangdong Province, Zhanjiang, [c]Department of Radiotherapy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Province, Nanjing, [d]Department of Radiotherapy, Zhejiang Cancer Hospital, Zhejiang Province, Hangzhou, China
出处：
DOI： 10.1097/MD.0000000000013014
ISSN：

关键词： brain metastasis concurrent EGFR mutation nonsmall cell lung cancer sequential tyrosine kinase inhibitors whole brain radiotherapy

摘要：
To examine the outcomes of concurrent versus sequential whole-brain radiotherapy (WBRT) and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in nonsmall cell lung cancer (NSCLC) patients with EGFR mutation. Retrospectively 105 patients with NSCLC, brain metastasis, and EGFR mutation (Affiliated Hospital of Guangdong Medical University, 01/2011 to 12/2014) were grouped as: EGFR-TKIs alone (n=39, group A), EGFR-TKIs+concurrent radiotherapy (n=34, group B), and radiotherapy followed by EGFR-TKIs (n=32, group C). The intracranial objective response rates of groups A, B, and C were 66.7%, 85.3%, and 75%, respectively (P<.05). The median intracranial progression-free survival of groups A, B, and C were 6.8, 12.4, and 9.1 months, respectively (P<.05). The median extracranial progression-free survival of groups A, B, and C were 7.8, 9.4, and 8.3 months, respectively (P>.05). EGFR-TKIs and WBRT by simultaneous application improved the short-and long-term benefits to patients with NSCLC brain metastasis carrying EGFR mutation compared to concurrent application or EGFR-TKIs alone without additional adverse events.

语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类 | 3 区 医学
小类 | 3 区 医学：内科
最新[2025]版：
大类 | 4 区 医学
小类 | 4 区 医学：内科
JCR分区：
出版当年[2016]版：
Q2 MEDICINE, GENERAL & INTERNAL
最新[2023]版：
Q2 MEDICINE, GENERAL & INTERNAL

影响因子： 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者：
第一作者机构： [a]Department of Oncology, the Second Affiliated Hospital of Soochow University, Jiangsu Province, Suzhou, [b]Cancer Center, Affiliated Hospital of Guangdong Medical University, Guangdong Province, Zhanjiang,
通讯作者：
通讯机构： [*1]Department of Oncology, the Second Affiliated Hospital of Soochow University, Jiangsu Province, Suzhou, China, Department of Radiotherapy, Zhejiang Cancer Hospital, Zhejiang Province, Hangzhou, China
推荐引用方式(GB/T 7714)：
Hualin Chen ,Aibing Wu ,Hua Tao ,et al.Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis A single institution retrospective analysis[J].MEDICINE.2018,97(44):e13014.doi:10.1097/MD.0000000000013014.
APA：
Hualin Chen,,Aibing Wu,,Hua Tao,,Donghong Yang,,Yiping Luo,...&Ming Chen,.(2018).Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis A single institution retrospective analysis.MEDICINE,97,(44)
MLA：
Hualin Chen,,et al."Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis A single institution retrospective analysis".MEDICINE 97..44(2018):e13014

相关文献

[1]The correlation between EGFR mutation status and the risk of brain metastasis in patients with lung adenocarcinoma [2]Management of brain metastases: History and the present [3]Clinical and radiological predictors of epidermal growth factor receptor mutation in nonsmall cell lung cancer [4]Efficacy and safety of PD-1 inhibitors plus anti-angiogenesis tyrosine kinase inhibitors with or without transarterial chemo(embolization) for unresectable hepatocellular carcinoma: a meta-analysis [5]Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS) [6]Relationship between circulating lung-specific X protein messenger ribonucleic acid expression and micrometastasis and prognosis in patients with early-stage nonsmall cell lung cancer [7]EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases [8]表皮生长因子受体酪氨酸激酶抑制剂治疗可手术非小细胞肺癌的研究进展 [9]Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease [10]Activation of G-Protein-Coupled Estrogen Receptor Inhibits the Migration of Human Nonsmall Cell Lung Cancer Cells via IKK-beta/NF-kappa B Signals

资源点击量：17070 今日访问量：0 总访问量：919 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持：重庆聚合科技有限公司 地址：北京市西城区长椿街45号宣武医院